User:Mr. Ibrahem/Ibrexafungerp

Mr. Ibrahem/Ibrexafungerp
Clinical data
Pronunciation	/aɪˌbrɛksəˈfʌndʒɜːrp/; eye-BREKS-ə-FUN-jurp
Trade names	Brexafemme
Other names	SCY-078
AHFS/Drugs.com	Monograph
License data	US DailyMed: Ibrexafungerp;
Pregnancy; category	Contraindicated;
Routes of; administration	By mouth, intravenous
Drug class	Antifungal
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hydroxylation (CYP3A4) then conjugation (glucuronidation, sulfation)
Elimination half-life	20 hours
Identifiers
	IUPAC name (1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid;
Chemical and physical data
Formula	C44H67N5O4
Molar mass	730.051 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@@H](n4ncnc4-c4ccncc4)[C@@H]5OC[C@](C)(N)C(C)(C)C)C3=CC[C@@]2(C)[C@@H]1C(=O)O;
	InChI InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1; Key:BODYFEUFKHPRCK-ZCZMVWJSSA-N;

Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vaginal yeast infection.^[1] It may be used in females after the start of menstruation.^[1] It is taken by mouth.^[1]

Common side effects include diarrhea, nausea, abdominal pain, and dizziness.^[1] Use in pregnancy may harm the baby.^[1] It is a triterpenoid antifungal and acts via blocking glucan synthase, which prevents formation of the fungal cell wall.^[1]

Ibrexafungerp was approved for medical use in the United States in 2021.^[1] It is not approved in Europe or the United Kingdom as of 2022.^[2] In the United States a course of treatment costs about 500 USD as of 2022.^[3]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p "Brexafemme- ibrexafungerp tablet, film coated". DailyMed. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
^ "Ibrexafungerp". SPS - Specialist Pharmacy Service. 2 August 2018. Archived from the original on 8 December 2021. Retrieved 29 October 2022.
^ "Ibrexafungerp". Archived from the original on 29 October 2022. Retrieved 29 October 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p "Brexafemme- ibrexafungerp tablet, film coated". DailyMed. Archived from the original on 12 September 2021. Retrieved 12 September 2021.

[SPS2022-2] "Ibrexafungerp". SPS - Specialist Pharmacy Service. 2 August 2018. Archived from the original on 8 December 2021. Retrieved 29 October 2022.

[3] "Ibrexafungerp". Archived from the original on 29 October 2022. Retrieved 29 October 2022.

[1]

[2]

[3]